ATE113470T1 - Gehirnspezifische zubereitung mit gesteuerter abgabe. - Google Patents

Gehirnspezifische zubereitung mit gesteuerter abgabe.

Info

Publication number
ATE113470T1
ATE113470T1 AT90115389T AT90115389T ATE113470T1 AT E113470 T1 ATE113470 T1 AT E113470T1 AT 90115389 T AT90115389 T AT 90115389T AT 90115389 T AT90115389 T AT 90115389T AT E113470 T1 ATE113470 T1 AT E113470T1
Authority
AT
Austria
Prior art keywords
brain
controlled delivery
specific preparation
active substance
pharmaceutically active
Prior art date
Application number
AT90115389T
Other languages
English (en)
Inventor
Toru Hayakawa
Toshiki Yoshimine
Keiji Fujioka
Yoshihiro Takada
Yoshio Sasaki
Tsunemasa Irie
Nobuyuki Fukushima
Original Assignee
Sumitomo Pharma
Koken Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma, Koken Kk filed Critical Sumitomo Pharma
Application granted granted Critical
Publication of ATE113470T1 publication Critical patent/ATE113470T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT90115389T 1989-08-10 1990-08-10 Gehirnspezifische zubereitung mit gesteuerter abgabe. ATE113470T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP20848489 1989-08-10

Publications (1)

Publication Number Publication Date
ATE113470T1 true ATE113470T1 (de) 1994-11-15

Family

ID=16556927

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90115389T ATE113470T1 (de) 1989-08-10 1990-08-10 Gehirnspezifische zubereitung mit gesteuerter abgabe.

Country Status (6)

Country Link
EP (1) EP0412554B1 (de)
JP (1) JP3187410B2 (de)
AT (1) ATE113470T1 (de)
DE (1) DE69013797T2 (de)
DK (1) DK0412554T3 (de)
ES (1) ES2066062T3 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2077763C (en) 1990-03-20 2007-07-31 Perry Bartlett Use of leukaemia inhibitory factor for regulating neuron development and maintenance
IT1240683B (it) * 1990-04-26 1993-12-17 Zambon Spa Composizione farmaceutica contenente egf
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
ATE226091T1 (de) * 1990-05-16 2002-11-15 Southern Res Inst Mikrokapseln mit gesteuerter freigabe sowie deren verwendung zur stimulierung des nervenfaserwachstums
DE4019208A1 (de) * 1990-06-15 1992-03-05 Peter Dr Med Wehling Nervenregenerationsmittel
WO1992017209A1 (fr) * 1991-04-08 1992-10-15 Sumitomo Pharmaceuticals Company, Limited Preparation solide poreuse contenant une substance proteique physiologiquement active
US5800390A (en) * 1991-05-24 1998-09-01 Sumitomo Pharmaceuticals Company, Limited Equipment for intracerebral administration of preparations
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
DE4237047A1 (en) * 1991-11-04 1993-05-06 I N R O Handels-Gmbh, 8750 Aschaffenburg, De Drug contg. polypeptide homologous to nerve growth factor and slow virus sequence - for treating amyotrophic lateral sclerosis, spinal muscle atrophy or Parkinson's disease
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
DE69327113D1 (de) * 1992-09-14 1999-12-30 Regeneron Pharma Methode zum erzeugen von analgie mittels neurotrophine
NZ311175A (en) * 1995-07-03 1999-11-29 Koken Co Gene preparation comprising a gene incorporated into a biocompatible carrier which preferably contains collagen
US6998268B2 (en) 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5780027A (en) * 1995-07-14 1998-07-14 Meiogen Biotechnology Corporation Methods of treatment of down syndrome by interferon antagonists
CA2252665A1 (en) * 1996-05-21 1997-11-27 Patrick Aebischer System and method for delivery of cytokines using encapsulated cytokine-secreting cells
ES2349137T3 (es) * 2000-06-20 2010-12-28 Dainippon Sumitomo Pharma Co., Ltd. Preparación para transferir oligonucleótidos.
ES2324525T3 (es) 2001-06-20 2009-08-10 Dainippon Sumitomo Pharma Co., Ltd. Metodo para promover transferencia de acidos nucleicos.
CN108840924A (zh) * 2018-06-20 2018-11-20 罗国球 一种高蛋白含量脑蛋白水解物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0139286B1 (de) * 1983-10-14 1991-08-21 Sumitomo Pharmaceuticals Company, Limited Verlängerte Präparate mit verzögerter Abgabe
EP0230647B1 (de) * 1985-12-27 1993-03-31 Sumitomo Pharmaceuticals Company, Limited Verfahren zur Herstellung einer Formulierung mit verzögerter Freisetzung
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier

Also Published As

Publication number Publication date
DK0412554T3 (da) 1994-12-12
JPH03163032A (ja) 1991-07-15
EP0412554A2 (de) 1991-02-13
ES2066062T3 (es) 1995-03-01
EP0412554A3 (en) 1991-09-25
DE69013797D1 (de) 1994-12-08
JP3187410B2 (ja) 2001-07-11
EP0412554B1 (de) 1994-11-02
DE69013797T2 (de) 1995-05-18

Similar Documents

Publication Publication Date Title
DE69013797D1 (de) Gehirnspezifische Zubereitung mit gesteuerter Abgabe.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
AU549481B2 (en) Hair growing agent
FI894361A7 (fi) Injektori lääkerakeiden ihonalaiseksi annostelemiseksi
AU4732989A (en) Pyrimidines and their pharmaceutical acceptable salts thereof, and their use as medicines
FI881876A7 (fi) Menetelmä neurologisten sairauksien hoitoon käytettävän koostumuksen valmistamiseksi.
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
RU93032613A (ru) Фармацевтический препарат для лечения пациентов с пролонгированным временем коагуляции, способ лечения пациентов, применение epi ингибитора для получения фармацевтического препарата
DK360188D0 (da) Laegemiddelafgivelsesorgan
DE69130586D1 (de) Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
EP0424156A3 (en) Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
DE69023459D1 (de) Behandlung von pulmonarer Disfunktion mit 15-Keto-prostaglandin-Derivaten.
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
EP0454429A3 (en) Use of 15-dehydroxy-16-oxoprostaglandin derivatives in the treatment of allergic diseases
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
NO875461D0 (no) Fremgangsmaate for fremstilling av et terapeutisk aktivt peptid.
DK15088D0 (da) Antibakterielt lyofiliseret praeparat
NO882282D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrazin-amider.
KR890700374A (ko) 전신에 유효한 약품의 경피 전달용 붕대
RU92013625A (ru) Лекарственное средство, стимулирующее эритроидный росток кроветворения при цитостатических миелодепрессиях
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee